ReviewInfectious diseases and therapy2026
Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review.
Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBone and joint infections (BJIs) are complex and difficult to eradicate, and have high relapse rates and limited oral treatment options. Tetracyclines combine favorable bone penetration, oral bioavailability, and activity against multidrug-resistant (MDR) pathogens, but their clinical role in BJIs remains unclear.
objectivesThis study aimed to summarize experimental and clinical evidence on tetracyclines in the management of BJIs, including pharmacology, antimicrobial activity, clinical efficacy, and guideline recommendations.
methodsWe performed a literature review of PubMed® (1960-2024) for animal, pharmacokinetic, and clinical studies evaluating tetracyclines in BJIs. Data on bone distribution, anti-biofilm activity, clinical outcomes, tolerability, and recommendations were extracted and synthesized.
resultsTetracyclines display strong bone affinity but inconsistent tissue concentrations in experimental models. In vitro and in vivo studies suggest anti-biofilm activity, particularly in combination with rifampicin, although monotherapy is insufficient. Two randomized controlled trials reported inferior outcomes compared with standard regimens. Observational studies of minocycline and tigecycline demonstrated variable efficacy (40-80%), with better outcomes in salvage therapy for MDR infections, but frequent gastrointestinal intolerance. Data on omadacycline remain limited to a single small cohort. Tetracyclines are recommended in guidelines for zoonotic infections (e.g., Brucella) and as long-term suppressive therapy in selected prosthetic joint infections, but evidence is weak compared with other agents, especially fluoroquinolones.
conclusionsTetracyclines may provide therapeutic options for refractory or MDR-related BJIs, and for suppressive therapy when surgical or antibiotic alternatives are limited. However, available data are heterogeneous and largely observational. Robust prospective studies are needed to clarify their role, particularly for newer agents such as omadacycline and eravacycline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.